Suppr超能文献

结核病的短程化疗:残酷的现实

Short-course chemotherapy of tuberculosis: the harsh realities.

作者信息

Iseman M D

机构信息

National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206.

出版信息

Semin Respir Infect. 1986 Dec;1(4):213-9.

PMID:3317613
Abstract

Recent studies have indicated that it is possible to successfully treat even far-advanced tuberculosis with a variety of chemotherapy regimens ranging in duration from 4.5 to 9 months. Furthermore, much or all of some regimens can be given twice-weekly. However, three major barriers remain to widespread success: (1) Noncompliance with prescribed treatment; (2) increasing prevalence of drug resistance; and, (3) sorely limited resources in impoverished segments of the third world. While noncompliance is responsible for a greater number of treatment failures, increasing levels of drug resistance pose a greater long-term threat due to a protracted carrier-vector state, soaring costs for adequate drug regimens, and--ultimately--the conversion of an imminently treatable infection into an unmanageable scourge--the resurrection of the "White Plague."

摘要

最近的研究表明,使用持续时间为4.5至9个月的各种化疗方案,即使是晚期结核病也有可能成功治愈。此外,一些方案的大部分或全部可以每周给药两次。然而,要广泛取得成功仍存在三大障碍:(1)不遵守规定的治疗;(2)耐药性患病率不断上升;以及(3)第三世界贫困地区资源极其有限。虽然不遵守规定导致更多治疗失败,但耐药性水平的上升构成了更大的长期威胁,原因是长期的带菌者-传播者状态、适当药物方案成本飙升,以及最终将一种即将可治疗的感染转变为一种无法控制的祸害——“白色瘟疫”的死灰复燃。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验